ValuEngine upgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE) from a strong sell rating to a sell rating in a research report released on Friday morning.

Separately, Zacks Investment Research upgraded Xenon Pharmaceuticals from a sell rating to a hold rating in a research report on Sunday, January 21st.

Xenon Pharmaceuticals (XENE) opened at $3.25 on Friday. Xenon Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.95. The stock has a market capitalization of $58.49, a P/E ratio of -2.04 and a beta of 1.46.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.35). Xenon Pharmaceuticals had a negative return on equity of 53.33% and a negative net margin of 4,268.70%. research analysts forecast that Xenon Pharmaceuticals will post -1.49 EPS for the current year.

In related news, Director Mohammad Azab acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $2.22 per share, for a total transaction of $33,300.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 9.40% of the company’s stock.

A hedge fund recently raised its stake in Xenon Pharmaceuticals stock. Scotia Capital Inc. raised its holdings in Xenon Pharmaceuticals Inc (NASDAQ:XENE) by 36.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 35,629 shares of the biopharmaceutical company’s stock after acquiring an additional 9,426 shares during the period. Scotia Capital Inc. owned 0.20% of Xenon Pharmaceuticals worth $112,000 at the end of the most recent reporting period. 54.60% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Xenon Pharmaceuticals (XENE) Lifted to Sell at ValuEngine” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/xenon-pharmaceuticals-xene-lifted-to-sell-at-valuengine/1845072.html.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.